A novel scheme for graft allocation in non-heart beating donor renal transplantation

Area of Science:

• Nephrology
• Transplantation Immunology
• Public Health Policy

Background:

• Long waiting times for renal transplants significantly impact patient outcomes.
• The allocation of kidneys from non-heart beating donors presents unique challenges and opportunities.
• Current UK National Allocation Scheme (NAS) may not optimally serve the longest-waiting patients.

Purpose of the Study:

• To evaluate a novel scoring system, the Bristol and Region Allocation by Non-heart beating Donor Score (BRANDS), for prioritizing patients awaiting renal transplants.
• To compare the outcomes of kidney transplants allocated via BRANDS versus the UK National Allocation Scheme (NAS) using non-heart beating donors.
• To assess the impact of BRANDS on reducing waiting times for renal transplant recipients.

Main Methods:

• A cohort of patients waiting over 3 years for a renal transplant was analyzed.
• Kidneys from 40 non-heart beating donors were allocated using the BRANDS score for one recipient and NAS for the other.
• Patient and graft survival rates, as well as renal function, were compared between the two allocation groups.

Main Results:

• The BRANDS allocation scheme reduced the number of patients waiting over 3 years by 20%.
• Despite increased dialysis time, sensitization, and HLA mismatches, BRANDS recipients showed equivalent 3-year graft survival (91% vs. 97%) and patient survival (94% vs. 92%) compared to NAS.
• BRANDS recipients had significantly lower renal function (40 vs. 62 mL/min/1.73 m2).

Conclusions:

• Transplanting long-waiting patients with kidneys from non-heart beating donors using the BRANDS system effectively reduces waiting times.
• Early graft and patient survival outcomes are comparable between BRANDS and NAS allocation methods.
• Long-term survival equivalence requires further investigation.